is compass pathways' psilocybin therapy close to fda approval?
“psilocybin coming from Compass uh a company called Compass Pathways is also close.”
a guest, author and journalist said on Huberman Lab, 2026-09-28, at 1:48:38. hear it in context →
first, the part that holds
the speaker is right: compass pathways' psilocybin program for treatment-resistant depression is the closest any classic psychedelic has come to a u.s. approval decision. two phase 3 trials met their primary endpoints, the fda allowed a rolling new drug application and gave the program a national priority voucher, and the company expects to finish its submission in q4 2026.
what we found when we went and looked
we read compass pathways' sec filings and the fda's april 24, 2026 announcement. the first phase 3 trial (258 participants) found a single 25 mg dose beat placebo by 3.6 points on the madrs depression scale at week 6 (95% ci -5.7 to -1.5, p<0.001). the second trial (nearly 600 patients) also met its primary endpoint: 39% of the 25 mg arm had a clinically meaningful response at week 6. as of august 5, 2026, the company said "rolling submission and initial review are underway, with some modules of the NDA submitted," with all modules due in q4 2026 and launch expected in the first half of 2027, "subject to FDA approval and following... DEA rescheduling." "close" is fair. one framing undersells it: the submission isn't "nearly" sufficient to file, because filing is already under way. what the record can't show yet is that approval will follow. the fda says a voucher "does not mean the drug has been approved or found to be safe or effective."
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| compass pathways' psilocybin therapy is close to fda approval | confirmed | the august 5, 2026 8-K says rolling submission and initial fda review are underway, all modules will be complete in q4 2026, and launch is expected in the first half of 2027, subject to fda approval and dea rescheduling. this is the company's own projection. the fda has made no approval decision, and none was possible before the final submission. [1][2] |
| the data are nearly sufficient for submission | undersold | the data stage is already done, and the regulatory submission has started. two phase 3 trials met their primary endpoints: the first by 3.6 madrs points over placebo at week 6 (p<0.001, n=258), the second with nearly 600 patients and 26-week follow-up. the fda granted a rolling review, and parts of the nda had been filed by the q1 and q2 2026 reports. whether the fda will judge the data sufficient for approval is a separate question it hasn't answered. [1][2][4] |
| the fda has signaled priority for this program | confirmed | on april 24, 2026 the fda announced national priority vouchers for three programs, one of them psilocybin for treatment-resistant depression. the fda page doesn't name the company; the company's filing says the voucher is for its program and could shorten review to 1-2 months. the fda adds that a voucher 'does not mean the drug has been approved or found to be safe or effective.' [1][3] |
both directions
for the speaker: two phase 3 trials hit their primary endpoints. in the first (258 participants), a single 25 mg dose beat placebo by 3.6 madrs points at week 6, 95% ci -5.7 to -1.5, p<0.001. the second (nearly 600 patients) reported 39% of the 25 mg arm with a clinically meaningful response at week 6, and on average responders kept the benefit through week 26. the company reports serious adverse events at similar rates in both arms over 26 weeks (6.3% at 1 mg, 5.7% at 25 mg). the fda granted a rolling nda review, and in april 2026 it issued national priority vouchers that include psilocybin for treatment-resistant depression. this voucher program is meant to shorten review to 1-2 months after filing. an earlier phase 2 trial, peer reviewed in the new england journal of medicine in 2022 (233 participants), also found 25 mg beat 1 mg at week 3, by -6.6 madrs points (95% ci -10.2 to -2.9, p<0.001).
against: "close" isn't approval, and two more steps lie outside the company's control. first, the fda has to review the application. second, the dea has to reschedule psilocybin, which is a schedule i substance, before any launch. the company's filings name both conditions. the phase 3 numbers come from the company, not from peer-reviewed papers. the company itself warns that full results "may not be consistent with the preliminary results to date." the effect over placebo is modest: 3.6 points on a 60-point scale at week 6, and the active-to-control difference shrank from the 6.6 points seen in phase 2. in the second trial, 39% had a meaningful response at 6 weeks, so most participants did not. in the 2022 phase 2 trial, sustained response at 12 weeks did not support the primary result, and "suicidal ideation or behavior or self-injury occurred in all dose groups." the fda says its voucher is no finding of safety or effectiveness. its april announcement names no company, so the link between this voucher and compass rests on the company's filing.
what this cannot say
as of october 6, 2026 the fda hadn't ruled, so nothing in the record can confirm or rule out approval, and any timeline is the company's projection. our phase 3 figures come from company press releases filed with the sec. those are legally regulated disclosures, but they aren't peer reviewed and don't report full secondary or safety tables. we didn't find or read a peer-reviewed publication of either phase 3 trial. we also didn't read the company's february 2026 release with the second trial's primary-endpoint effect size, so we don't cite that number. the only peer-reviewed efficacy data we read is the 2022 phase 2 trial. "close" is a vague word; we read it as "submission under way, decision expected within about a year." a stricter reading could rate it differently.
sources, each one fetched and read
- COMPASS Pathways plc, Form 8-K exhibit, second quarter 2026 results press release, US SEC EDGAR, August 5, 2026 What we read there: "Rolling submission and initial review are underway, with some modules of the NDA submitted and on track to complete all modules in Q4"; commercial launch expected in first half of 2027 subject to FDA approval and DEA rescheduling; "full results and safety data from our Phase 3 clinical trials in TRD may not be consistent with the preliminary results to date." Fetched 2026-10-06 (HTTP 200). https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000059/q22026pressrelease.htm
- COMPASS Pathways plc, Form 8-K, second phase 3 trial (COMP006) 26-week results, US SEC EDGAR, July 7, 2026 What we read there: nearly 600 patients; "39% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS (≥ 25%) at Week 6"; serious adverse events 6.3% in the 1 mg arm and 5.7% in the 25 mg arm over 26 weeks; "final submission remains on track to be completed in Q4, 2026." Fetched 2026-10-06 (HTTP 200). https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000047/cmps-20260707.htm
- US Food and Drug Administration, 'FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order', press announcement, April 24, 2026 What we read there: national priority vouchers issued for programs studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD; the FDA states its decision 'does not mean the drug has been approved or found to be safe or effective.' Fetched 2026-10-06 (HTTP 200). https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order
- COMPASS Pathways plc, Form 8-K, first phase 3 trial (COMP005) primary endpoint, US SEC EDGAR, June 23, 2025 What we read there: 258 participants across 32 US sites; "Single dose of COMP360 25 mg versus placebo with a mean treatment difference of -3.6 points, 95% CI [-5.7, -1.5]; p<0.001" at week 6; FDA "has not yet reviewed the data." Fetched 2026-10-06 (HTTP 200). https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm
- Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443. PMID 36322843 What we read there: 79 participants at 25 mg, 75 at 10 mg, 79 at 1 mg; difference between 25 mg and 1 mg at week 3 was -6.6 (95% CI -10.2 to -2.9; P<0.001); sustained response at 12 weeks not supportive; "Suicidal ideation or behavior or self-injury occurred in all dose groups"; larger and longer trials required. Fetched 2026-10-06 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/36322843/
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam